Search details
1.
Extended peptide receptor radionuclide therapy: evaluating nephrotoxicity and therapeutic effectiveness in neuroendocrine tumor patients receiving more than four treatment cycles.
Eur J Nucl Med Mol Imaging
; 51(4): 1136-1146, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38040931
2.
A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging.
Eur J Nucl Med Mol Imaging
; 51(6): 1685-1697, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38246909
3.
Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013.
Eur J Nucl Med Mol Imaging
; 2024 Apr 02.
Article
in English
| MEDLINE | ID: mdl-38561515
4.
Tumour-associated B cells in urothelial urinary bladder cancer.
Scand J Immunol
; 91(2): e12830, 2020 Feb.
Article
in English
| MEDLINE | ID: mdl-31823416
5.
Exploiting Albumin as a Versatile Carrier for Cancer Theranostics.
Acc Chem Res
; 56(18): 2403-2415, 2023 09 19.
Article
in English
| MEDLINE | ID: mdl-37625245
6.
Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Theranostics
; 14(1): 133-142, 2024.
Article
in English
| MEDLINE | ID: mdl-38164147
7.
Long-term Nephrotoxicity after PRRT: Myth or Reality.
Theranostics
; 14(2): 451-459, 2024.
Article
in English
| MEDLINE | ID: mdl-38169589
8.
A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers.
Clin Nucl Med
; 48(10): 861-868, 2023 Oct 01.
Article
in English
| MEDLINE | ID: mdl-37682601
9.
Dual targeting PET tracer [68Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study.
Theranostics
; 13(9): 2979-2992, 2023.
Article
in English
| MEDLINE | ID: mdl-37284441
10.
Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists.
Front Med (Lausanne)
; 9: 1034315, 2022.
Article
in English
| MEDLINE | ID: mdl-36569154
Results
1 -
10
de 10
1
Next >
>>